What is HeartFlow?
HeartFlow operates at the intersection of advanced medical technology and human ingenuity, providing clinicians with non-invasive, actionable insights into coronary artery disease. By leveraging proprietary computational fluid dynamics, the company has established a unique market position, effectively bridging the gap between traditional diagnostic imaging and interventional cardiology. As a leader in precision heart care, HeartFlow continues to push the boundaries of clinical diagnostics, ensuring that healthcare providers have the data necessary to make informed, patient-centric decisions. The company's commitment to innovation has solidified its reputation as a transformative force in the healthcare landscape, attracting significant institutional backing from top-tier venture capital and private equity firms.
How much funding has HeartFlow raised?
HeartFlow has raised a total of $890.7M across 11 funding rounds:
Series C
$104.7M
Unspecified
$35.9M
Series D
$99.9M
Series E
$240M
Unspecified
$65M
Series F
$215M
Other Financing Round
$98M
Series C (2014): $104.7M backed by Orkila Capital, LLC, U.S. Venture Partners, HealthCor Partners Management, Sandbox Industries Inc., and Capricorn Investment Group, LLC
Unspecified (2015): $35.9M with participation from U.S. Venture Partners and Capricorn Investment Group
Series D (2016): $99.9M led by Panorama Point Partners
Series E (2018): $240M supported by GE Ventures, Blue Cross Blue Shield, Wellington Management, Baillie Gifford, U.S. Venture Partners, and Rancilio Cube srl
Unspecified (2019): $65M, investors not publicly disclosed
Series F (2023): $215M backed by HealthCor Partners Management, Wellington Management, Baillie Gifford, Hayfin, Martis Capital, Bain Capital Life Sciences, Capricorn Investment Group, USVP Management, and Janus Henderson Investors
Other Financing Round (2025): $98M with participation from Capricorn Group, US Venture Partners, HealthCor Partners Management, Fidelity, Bain Capital, Martis Capital, and Hayfin
Key Investors in HeartFlow
U.S. Venture Partners
U.S. Venture Partners is a prominent Silicon Valley venture capital firm specializing in early-stage investments across healthcare, cybersecurity, and enterprise software, leveraging a deep network of technologists to support scaling.
HealthCor Partners Management
HealthCor Partners Management focuses on growth equity and later-stage developmental companies within the healthcare and life sciences industry, utilizing fundamental research to drive investment strategy.
Capricorn Investment Group
Capricorn Investment Group manages diversified portfolios for institutional investors and families, with a strong emphasis on impact, sustainable, and growth-oriented investments.
What's next for HeartFlow?
With the successful closure of this major enterprise-level funding, HeartFlow is well-positioned to scale its operations and deepen its research and development initiatives. The strategic capital will likely be deployed to enhance the company's diagnostic platform, explore new clinical applications, and strengthen its commercial partnerships. As the firm transitions into its next phase of maturity, the focus remains on scaling its impact within the global healthcare ecosystem, ensuring that its precision care solutions become the standard for managing complex cardiovascular conditions. By maintaining a rigorous focus on clinical outcomes and technological advancement, HeartFlow is poised to sustain its competitive advantage and drive long-term value for its stakeholders.
See full HeartFlow company page
